希罗达联合多西他赛治疗晚期乳腺癌患者的近期疗效观察

The short- term efficacy of docetaxel combined with xeloda in the treatment of patients with advanced breast cancer

目的研究希罗达联合多西他赛治疗耐蒽环类药物的晚期乳腺癌的近期疗效和不良反应。方法对52例晚期乳腺癌患者给予希罗达和多西他赛药物联合治疗,希罗达2 500 mg/(m2·d),分2次服用,早晚各1次,饭后30 min口服,连服14 d;多西他赛75 mg/m2,第1天静脉滴注,21 d为1个疗程,4个周期后开始评价疗效和不良反应。结果疾病完全控制者(CR)7例,部分缓解者(PR)27例,稳定者(SD)8例,疾病进展者(PD)10例,总有效率为65.4%,肿瘤控制率为80.7%。不良反应主要为脱发、骨髓抑制、胃肠道反应、手足综合征、皮肤色素沉着、肌肉疼痛,未发生治疗相关性死亡。结论希罗达联合多西他赛对耐蒽环类药物的晚期乳腺癌患者有明显的疗效,不良反应可以耐受,值得临床上推广和应用。

Objective To observe the clinical efficacy and adverse effect of docetaxel combined with xeloda in the treatment of patients with advanced breast cancer after failure of anthracycline -based treatment.Methods Fifty -two patients with ad-vanced breast cancer were treated with docetaxel combined and xeloda.Xeloda 2 500 mg/（m2·d）,30 min after a meal,twice daily,lasting for fourteen days;docetaxel 75 mg/m2 ivgtt,day 1 ,repeated every three weeks as one cycle.Each patient received 4 cycles chemotherapy at least.The efficacy and side effect were reviewed after chemotherapy.Results There were 7 cases of complete response（CR）,27 cases of partial response（PR）,8 cases of stable disease（SD）and 1 0 cases of progressive disease （PD）,the total effective rate was 65.4%,and tumor control rate was 80.7%.The main adverse effects were hair loss,bone marrow suppression,gastrointestinal reactions,extremities syndrome,skin pigmentation,muscle pain.There was no treatment -related death.Conclusion Docetaxel combined with xeloda was effective in the treatment of patients with advanced breast canc-er after failure of anthracycline -based treatment.The adverse reactions could be tolerated.It is worth clinical promotion and ap-plication.